Cargando…
Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial
INTRODUCTION: Atrial fibrillation is the most common heart arrhythmia with a prevalence of approximately 2% in the western world. Atrial fibrillation is associated with an increased risk of death and morbidity. In many patients, a rate control strategy is recommended. The optimal heart rate target i...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016086/ https://www.ncbi.nlm.nih.gov/pubmed/33789853 http://dx.doi.org/10.1136/bmjopen-2020-044744 |
_version_ | 1783673784823185408 |
---|---|
author | Feinberg, Joshua Buron Olsen, Michael Hecht Brandes, Axel Raymond, llan Nielsen, Walter Bjørn Nielsen, Emil Eik Stensgaard-Hansen, Frank Dixen, Ulrik Pedersen, Ole Dyg Gang, Uffe Jakob Ortved Gluud, Christian Jakobsen, Janus Christian |
author_facet | Feinberg, Joshua Buron Olsen, Michael Hecht Brandes, Axel Raymond, llan Nielsen, Walter Bjørn Nielsen, Emil Eik Stensgaard-Hansen, Frank Dixen, Ulrik Pedersen, Ole Dyg Gang, Uffe Jakob Ortved Gluud, Christian Jakobsen, Janus Christian |
author_sort | Feinberg, Joshua Buron |
collection | PubMed |
description | INTRODUCTION: Atrial fibrillation is the most common heart arrhythmia with a prevalence of approximately 2% in the western world. Atrial fibrillation is associated with an increased risk of death and morbidity. In many patients, a rate control strategy is recommended. The optimal heart rate target is disputed despite the results of the the RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient vs strict rate control II (RACE II) trial. Our primary objective will be to investigate the effect of lenient rate control strategy (<110 beats per minute (bpm) at rest) compared with strict rate control strategy (<80 bpm at rest) on quality of life in patients with persistent or permanent atrial fibrillation. METHODS AND ANALYSIS: We plan a two-group, superiority randomised clinical trial. 350 outpatients with persistent or permanent atrial fibrillation will be recruited from four hospitals, across three regions in Denmark. Participants will be randomised 1:1 to a lenient medical rate control strategy (<110 bpm at rest) or a strict medical rate control strategy (<80 bpm at rest). The recruitment phase is planned to be 2 years with 3 years of follow-up. Recruitment is expected to start in January 2021. The primary outcome will be quality of life using the Short Form-36 (SF-36) questionnaire (physical component score). Secondary outcomes will be days alive outside hospital, symptom control using the Atrial Fibrillation Effect on Quality of Life, quality of life using the SF-36 questionnaire (mental component score) and serious adverse events. The primary assessment time point for all outcomes will be 1 year after randomisation. ETHICS AND DISSEMINATION: Ethics approval was obtained through the ethics committee in Region Zealand. The design and findings will be published in peer-reviewed journals as well as be made available on ClinicalTrials.gov. TRIAL REGISTRATION NUMBER: NCT04542785. |
format | Online Article Text |
id | pubmed-8016086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-80160862021-04-21 Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial Feinberg, Joshua Buron Olsen, Michael Hecht Brandes, Axel Raymond, llan Nielsen, Walter Bjørn Nielsen, Emil Eik Stensgaard-Hansen, Frank Dixen, Ulrik Pedersen, Ole Dyg Gang, Uffe Jakob Ortved Gluud, Christian Jakobsen, Janus Christian BMJ Open Cardiovascular Medicine INTRODUCTION: Atrial fibrillation is the most common heart arrhythmia with a prevalence of approximately 2% in the western world. Atrial fibrillation is associated with an increased risk of death and morbidity. In many patients, a rate control strategy is recommended. The optimal heart rate target is disputed despite the results of the the RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient vs strict rate control II (RACE II) trial. Our primary objective will be to investigate the effect of lenient rate control strategy (<110 beats per minute (bpm) at rest) compared with strict rate control strategy (<80 bpm at rest) on quality of life in patients with persistent or permanent atrial fibrillation. METHODS AND ANALYSIS: We plan a two-group, superiority randomised clinical trial. 350 outpatients with persistent or permanent atrial fibrillation will be recruited from four hospitals, across three regions in Denmark. Participants will be randomised 1:1 to a lenient medical rate control strategy (<110 bpm at rest) or a strict medical rate control strategy (<80 bpm at rest). The recruitment phase is planned to be 2 years with 3 years of follow-up. Recruitment is expected to start in January 2021. The primary outcome will be quality of life using the Short Form-36 (SF-36) questionnaire (physical component score). Secondary outcomes will be days alive outside hospital, symptom control using the Atrial Fibrillation Effect on Quality of Life, quality of life using the SF-36 questionnaire (mental component score) and serious adverse events. The primary assessment time point for all outcomes will be 1 year after randomisation. ETHICS AND DISSEMINATION: Ethics approval was obtained through the ethics committee in Region Zealand. The design and findings will be published in peer-reviewed journals as well as be made available on ClinicalTrials.gov. TRIAL REGISTRATION NUMBER: NCT04542785. BMJ Publishing Group 2021-03-31 /pmc/articles/PMC8016086/ /pubmed/33789853 http://dx.doi.org/10.1136/bmjopen-2020-044744 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Cardiovascular Medicine Feinberg, Joshua Buron Olsen, Michael Hecht Brandes, Axel Raymond, llan Nielsen, Walter Bjørn Nielsen, Emil Eik Stensgaard-Hansen, Frank Dixen, Ulrik Pedersen, Ole Dyg Gang, Uffe Jakob Ortved Gluud, Christian Jakobsen, Janus Christian Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial |
title | Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial |
title_full | Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial |
title_fullStr | Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial |
title_full_unstemmed | Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial |
title_short | Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial |
title_sort | lenient rate control versus strict rate control for atrial fibrillation: a protocol for the danish atrial fibrillation (danaf) randomised clinical trial |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016086/ https://www.ncbi.nlm.nih.gov/pubmed/33789853 http://dx.doi.org/10.1136/bmjopen-2020-044744 |
work_keys_str_mv | AT feinbergjoshuaburon lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT olsenmichaelhecht lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT brandesaxel lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT raymondllan lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT nielsenwalterbjørn lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT nielsenemileik lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT stensgaardhansenfrank lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT dixenulrik lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT pedersenoledyg lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT ganguffejakobortved lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT gluudchristian lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial AT jakobsenjanuschristian lenientratecontrolversusstrictratecontrolforatrialfibrillationaprotocolforthedanishatrialfibrillationdanafrandomisedclinicaltrial |